Literature DB >> 28786414

Breast cancer: What lies beyond APHINITY for HER2-positive breast cancer?

Sasha E Stanton1, Nancy E Davidson2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28786414     DOI： 10.1038/nrclinonc.2017.125

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial.

Authors:  G Bianchini; L Pusztai; T Pienkowski; Y-H Im; G V Bianchi; L-M Tseng; M-C Liu; A Lluch; E Galeota; D Magazzù; J de la Haba-Rodríguez; D-Y Oh; B Poirier; J L Pedrini; V Semiglazov; P Valagussa; L Gianni
Journal:  Ann Oncol       Date:  2015-09-19       Impact factor: 32.976

2.  Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

Authors:  Sara M Tolaney; William T Barry; Chau T Dang; Denise A Yardley; Beverly Moy; P Kelly Marcom; Kathy S Albain; Hope S Rugo; Matthew Ellis; Iuliana Shapira; Antonio C Wolff; Lisa A Carey; Beth A Overmoyer; Ann H Partridge; Hao Guo; Clifford A Hudis; Ian E Krop; Harold J Burstein; Eric P Winer
Journal:  N Engl J Med       Date:  2015-01-08       Impact factor: 91.245

3.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

Authors:  Luca Gianni; Tadeusz Pienkowski; Young-Hyuck Im; Laslo Roman; Ling-Ming Tseng; Mei-Ching Liu; Ana Lluch; Elżbieta Staroslawska; Juan de la Haba-Rodriguez; Seock-Ah Im; Jose Luiz Pedrini; Brigitte Poirier; Paolo Morandi; Vladimir Semiglazov; Vichien Srimuninnimit; Giulia Bianchi; Tania Szado; Jayantha Ratnayake; Graham Ross; Pinuccia Valagussa
Journal:  Lancet Oncol       Date:  2011-12-06       Impact factor: 41.316

4.  5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.

Authors:  Luca Gianni; Tadeusz Pienkowski; Young-Hyuck Im; Ling-Ming Tseng; Mei-Ching Liu; Ana Lluch; Elżbieta Starosławska; Juan de la Haba-Rodriguez; Seock-Ah Im; Jose Luiz Pedrini; Brigitte Poirier; Paolo Morandi; Vladimir Semiglazov; Vichien Srimuninnimit; Giulia Valeria Bianchi; Domenico Magazzù; Virginia McNally; Hannah Douthwaite; Graham Ross; Pinuccia Valagussa
Journal:  Lancet Oncol       Date:  2016-05-11       Impact factor: 41.316

5.  Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

Authors:  Gunter von Minckwitz; Marion Procter; Evandro de Azambuja; Dimitrios Zardavas; Mark Benyunes; Giuseppe Viale; Thomas Suter; Amal Arahmani; Nathalie Rouchet; Emma Clark; Adam Knott; Istvan Lang; Christelle Levy; Denise A Yardley; Jose Bines; Richard D Gelber; Martine Piccart; Jose Baselga
Journal:  N Engl J Med       Date:  2017-06-05       Impact factor: 91.245

6.  Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

Authors:  Sandra M Swain; José Baselga; Sung-Bae Kim; Jungsil Ro; Vladimir Semiglazov; Mario Campone; Eva Ciruelos; Jean-Marc Ferrero; Andreas Schneeweiss; Sarah Heeson; Emma Clark; Graham Ross; Mark C Benyunes; Javier Cortés
Journal:  N Engl J Med       Date:  2015-02-19       Impact factor: 91.245

7.  Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.

Authors:  Martine Piccart-Gebhart; Eileen Holmes; José Baselga; Evandro de Azambuja; Amylou C Dueck; Giuseppe Viale; Jo Anne Zujewski; Aron Goldhirsch; Alison Armour; Kathleen I Pritchard; Ann E McCullough; Stella Dolci; Eleanor McFadden; Andrew P Holmes; Liu Tonghua; Holger Eidtmann; Phuong Dinh; Serena Di Cosimo; Nadia Harbeck; Sergei Tjulandin; Young-Hyuck Im; Chiun-Sheng Huang; Véronique Diéras; David W Hillman; Antonio C Wolff; Christian Jackisch; Istvan Lang; Michael Untch; Ian Smith; Frances Boyle; Binghe Xu; Henry Gomez; Thomas Suter; Richard D Gelber; Edith A Perez
Journal:  J Clin Oncol       Date:  2015-11-23       Impact factor: 44.544

Review 8.  Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review.

Authors:  Sasha E Stanton; Sylvia Adams; Mary L Disis
Journal:  JAMA Oncol       Date:  2016-10-01       Impact factor: 31.777

9.  Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

Authors:  L Arnould; M Gelly; F Penault-Llorca; L Benoit; F Bonnetain; C Migeon; V Cabaret; V Fermeaux; P Bertheau; J Garnier; J-F Jeannin; B Coudert
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

10.  Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.

Authors:  Jashodeep Datta; Erik Berk; Shuwen Xu; Elizabeth Fitzpatrick; Cinthia Rosemblit; Lea Lowenfeld; Noah Goodman; David A Lewis; Paul J Zhang; Carla Fisher; Robert E Roses; Angela DeMichele; Brian J Czerniecki
Journal:  Breast Cancer Res       Date:  2015-05-23       Impact factor: 6.466
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.